The PennZone

  • Home
  • Non-profit
  • Business
  • Education
  • Technology
  • Construction
  • Entertainment
  • Health
  • Software

Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
The PennZone/10289107

Trending...
  • Global.ai Appoints Freedomtech Solutions as Specialist Partner for Agentic AI
  • Autism Podcast Helps Parents Understand Why Behavior Is Communication, Not Defiance
  • Love Must Be the Guide: Live Good Shares a Message of Humanity, Compassion and Hope
PHILADELPHIA, Nov. 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: https://www.prnewswire.com/news-releases/#finan..." rel="nofollow">CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Thursday, December 5th at 9:35 am ET.

An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.

More on The PennZone
  • AI Velocity Trading Launches Institutional-Grade Algorithmic Engine for Retail Investors
  • America's Workforce Solution, LLC Assessed "Awardable" for Department of War work in the CDAO's Tradewinds Solutions Marketplace
  • Speaker and Certified Coach Syrena N. Williams Debuts Powerful New Book on Healing, Identity, and Wholeness
  • Lord of the Rings, Doctor Who' Q&As, Local Sessions Highlight FAN EXPO Philadelphia Programming
  • Kryptokasinot.io Raises Concerns Over Proposed Cryptocurrency Restrictions in Finland's Gambling Reform

About Carisma

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.

Investors:
Shveta Dighe
Head of Investor Relations
[email protected]

Media Contact:
Julia Stern
(763) 350-5223
[email protected]

SOURCE Carisma Therapeutics Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • AI-Powered Trading Bots Are Transforming Forex, Gold, and Digital Markets as DefiHash Expands Intelligent Quantitative Infrastructure
  • Early Bird Registration Open for FLYING HY, the Top Hydrogen and Battery Electric Aviation Event
  • Eichelberger Performing Arts Center Welcomes New Executive Director
  • Century Fasteners Corp. Hires Tony Marano as Director of Human Resources
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
  • New Wisconsin Report Shows Most Plane Crashes Happen Outside Major Hubs
  • Thou Shalt not Commit Adultery Lifetime Movie Discussion
  • Book Florida Keys Accommodations Early with KeysCaribbean and Save 15 Percent
  • Color Card Administrator Highlights Growing Enterprise Demand for Workflow Orchestration in Enterprise Business Card Governance
  • Tennessee Laws Lead with Psychotropic Drug Testing in Mass Shooting Cases and Comprehensive Reporting: CCHR Urges Nationwide Adoption
  • Curious About Mensa? DFW Event Offers a 1-Day Immersion
  • Morphy's will breeze into summer with a June 10-11 Fine & Decorative Arts auction featuring nearly 1,200 high-quality lots
  • L-Tron to Exhibit at American Association for Motor Vehicle Administrators Region 1 Conference
  • Buzzblender Announces Launch of Simple Hotel Mode for Android and Upcoming Video Wall Support for Samsung Professional Displays
  • How Strategic WooCommerce Development and Digital Marketing Helped a Fashion Ecommerce Business Increase Revenue by 3X
  • Burkentine Builders Breaks Ground For Two New Communities
  • VIV Welcomes Residents to St. Petersburg's EDGE District
  • Evocative Joins the Independent Data Centre Network (IDCN) as Primary USA Operator
  • Philadelphia Scientist Roohid Parast Advances IBD Research at Johnson & Johnson
  • Medical Experts Highlight the Importance of Second Opinions in Death Investigations

Popular on PennZone

  • Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
  • People & Stories/Gente y Cuentos Welcomes Two New Trustees as Organization Enters 54th Year and Expands Community Reach
  • Assymetrix Launches the Deepest Independent Prediction Market Data API
  • Strategic Talent Associates Launches THE ALIGNED RESET™
  • AWARENESS TO WELLNESS: Imhotep Institute Charter High School
  • Resident Inspect Joins Property Meld Nexus Network with API Integration
  • New plusOne Research Finds the Orgasm Gap Is a 30-Point Chasm — and Confirms It Isn't Biology
  • New Homesites Released at Heritage at Manalapan Featuring Scenic Golf Course Views
  • RAS AP Consulting Advances to RFP Stage in Heidelberg Materials' SAP Vendor & Customer Master Data Modernization Initiative
  • Expert E-Bike Safety Advocate Issues Urgent Warning Following Recent Southern California Fatalities

Similar on PennZone

  • Milton Collier, CEO & President of Freight Broker 911, Eliminates the #1 Barrier to Entry in Logistics: Announces 100% Free Freight Broker Training
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
  • KRE PRIME Launches Adaptive Convertible Jumpsuit
  • Sobreseimiento de Nicolás dos Santos y Jorge Méndez expone demandas millonarias a Paraguay y boicot a la Hidrovía
  • UK Financial Ltd Executes 100% Success Rate on All ERC-3643 Transfers to Coin Holders of MayaCat Regulated Security Token and Maya Preferred PRA
  • Global.ai Appoints Freedomtech Solutions as Specialist Partner for Agentic AI
  • Triple-Digit Growth, OTCQX Market Upgrade and a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation: Stock Symbol: CDIX
  • XRPPower Continues Strengthening Its Global AI-Powered Blockchain Ecosystem
  • Advanced AI Capabilities Reflected by Upcoming Company Name and Stock Symbol Change for Evolving Pre-Owned Boat Dealer: Off The Hook YS: N Y S E: OTH
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us